Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KBV Research | PRODUCT CODE: 1245506

Cover Image

PUBLISHER: KBV Research | PRODUCT CODE: 1245506

North America Onychomycosis Market Size, Share & Industry Trends Analysis Report By Type (Distal Subungual, Proximal Subungual, White Superficial and Others), By Treatment (Topical, Oral and Others), By Country and Growth Forecast, 2022 - 2028

PUBLISHED:
PAGES: 72 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1500
PDF (Site License)
USD 1800
PDF (Enterprisewide License)
USD 2520

Add to Cart

The North America Onychomycosis Market would witness market growth of 4.2% CAGR during the forecast period (2022-2028).

Onychomycosis can be brought on by a variety of fungi, including Fusarium and dermatophytes. Risk factors include athletes' foot or some other nail/foot conditions, peripheral vascular disease, contact with those who have it, and a weakened immune system. Usually, based on the appearance, the diagnosis is speculated, and laboratory testing is used to confirm it. Numerous kinds of fungi that are present in the environment cause fungus-related nail diseases. These germs can enter the nail through tiny holes in the skin around it or in the nail, inflicting an infection.

The most effective course of treatment for fungus nail infections is to begin early, frequently through oral administration of prescription antifungal medications. In extreme circumstances, a medical practitioner might fully remove the nail. However, the illness may take a few months to one year to clear up. Fungal skin infections can often occur with fungal nail infections. In addition, the fungal infection spreads from one location to another if it is not treated. Fungal infections can recur even after therapy.

The prevalence of diabetes and the aging population in the region are the primary factors propelling the region's onychomycosis treatment demand. More than 3 million Canadians are diagnosed to be suffering from diabetes. Moreover, in 2016, the Census Bureau estimated that there were around 49.2 million Americans who were 65 or older, with one-fourth of them residing in one of the three states of California, Florida, or Texas. Seven additional states-Georgia, Illinois, Michigan, and New York-make up another quarter of the population aged 65 and over. This supports the growth of the regional market.

The US market dominated the North America Onychomycosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,287.9 Million by 2028. The Canada market is poised to grow at a CAGR of 6.5% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 5.6% during (2022 - 2028).

Based on Type, the market is segmented into Distal Subungual, Proximal Subungual, White Superficial and Others. Based on Treatment, the market is segmented into Topical, Oral and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Distal Subungual
  • Proximal Subungual
  • White Superficial
  • Others

By Treatment

  • Topical
  • Oral
  • Others

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Companies Profiled

  • Pfizer, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Abbott Laboratories
  • Bausch Health Companies, Inc.
  • Bayer AG
  • Cipla Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • GlaxoSmithKline PLC

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 North America Onychomycosis Market, by Type
    • 1.4.2 North America Onychomycosis Market, by Treatment
    • 1.4.3 North America Onychomycosis Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition & Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. North America Onychomycosis Market by Type

  • 3.1 North America Distal Subungual Market by Country
  • 3.2 North America Proximal Subungual Market by Country
  • 3.3 North America White Superficial Market by Country
  • 3.4 North America Others Market by Country

Chapter 4. North America Onychomycosis Market by Treatment

  • 4.1 North America Topical Market by Country
  • 4.2 North America Oral Market by Country
  • 4.3 North America Others Market by Country

Chapter 5. North America Onychomycosis Market by Country

  • 5.1 US Onychomycosis Market
    • 5.1.1 US Onychomycosis Market by Type
    • 5.1.2 US Onychomycosis Market by Treatment
  • 5.2 Canada Onychomycosis Market
    • 5.2.1 Canada Onychomycosis Market by Type
    • 5.2.2 Canada Onychomycosis Market by Treatment
  • 5.3 Mexico Onychomycosis Market
    • 5.3.1 Mexico Onychomycosis Market by Type
    • 5.3.2 Mexico Onychomycosis Market by Treatment
  • 5.4 Rest of North America Onychomycosis Market
    • 5.4.1 Rest of North America Onychomycosis Market by Type
    • 5.4.2 Rest of North America Onychomycosis Market by Treatment

Chapter 6. Company Profiles

  • 6.1 Abbott Laboratories
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Segmental and Regional Analysis
    • 6.1.4 Research & Development Expense
    • 6.1.5 SWOT Analysis
  • 6.2 Bausch Health Companies, Inc.
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Segmental and Regional Analysis
    • 6.2.4 Research & Development Expense
    • 6.2.5 Recent strategies and developments:
      • 6.2.5.1 Trials and Approvals:
  • 6.3 Bayer AG
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Segmental and Regional Analysis
    • 6.3.4 Research & Development Expense
    • 6.3.5 Recent strategies and developments:
      • 6.3.5.1 Product Launches and Expansions:
  • 6.4 Cipla Limited
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Regional Analysis
    • 6.4.4 Research & Development Expense
    • 6.4.5 Recent strategies and developments:
      • 6.4.5.1 Product Launches and Product Expansions:
  • 6.5 Sun Pharmaceutical Industries Ltd.
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Regional & Segmental Analysis
    • 6.5.4 Research & Development Expenses
    • 6.5.5 Recent strategies and developments:
      • 6.5.5.1 Acquisition and Mergers:
  • 6.6 GlaxoSmithKline PLC (GSK)
    • 6.6.1 Company Overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Segmental and Regional Analysis
    • 6.6.4 Research & Development Expense
    • 6.6.5 Recent strategies and developments:
      • 6.6.5.1 Partnerships, Collaborations, and Agreements:
  • 6.7 Pfizer, Inc.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Regional & Segmental Analysis
    • 6.7.4 Research & Development Expense
  • 6.8 Teva Pharmaceutical Industries Ltd.
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Regional Analysis
    • 6.8.4 Research & Development Expenses
  • 6.9 Merck & Co., Inc.
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Segmental and Regional Analysis
    • 6.9.4 Research & Development Expenses
  • 6.10. Novartis AG
    • 6.10.1 Company Overview
    • 6.10.2 Financial Analysis
    • 6.10.3 Segmental and Regional Analysis
    • 6.10.4 Research & Development Expense

LIST OF TABLES

  • TABLE 1 North America Onychomycosis Market, 2018 - 2021, USD Million
  • TABLE 2 North America Onychomycosis Market, 2022 - 2028, USD Million
  • TABLE 3 North America Onychomycosis Market by Type, 2018 - 2021, USD Million
  • TABLE 4 North America Onychomycosis Market by Type, 2022 - 2028, USD Million
  • TABLE 5 North America Distal Subungual Market by Country, 2018 - 2021, USD Million
  • TABLE 6 North America Distal Subungual Market by Country, 2022 - 2028, USD Million
  • TABLE 7 North America Proximal Subungual Market by Country, 2018 - 2021, USD Million
  • TABLE 8 North America Proximal Subungual Market by Country, 2022 - 2028, USD Million
  • TABLE 9 North America White Superficial Market by Country, 2018 - 2021, USD Million
  • TABLE 10 North America White Superficial Market by Country, 2022 - 2028, USD Million
  • TABLE 11 North America Others Market by Country, 2018 - 2021, USD Million
  • TABLE 12 North America Others Market by Country, 2022 - 2028, USD Million
  • TABLE 13 North America Onychomycosis Market by Treatment, 2018 - 2021, USD Million
  • TABLE 14 North America Onychomycosis Market by Treatment, 2022 - 2028, USD Million
  • TABLE 15 North America Topical Market by Country, 2018 - 2021, USD Million
  • TABLE 16 North America Topical Market by Country, 2022 - 2028, USD Million
  • TABLE 17 North America Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 18 North America Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 19 North America Others Market by Country, 2018 - 2021, USD Million
  • TABLE 20 North America Others Market by Country, 2022 - 2028, USD Million
  • TABLE 21 North America Onychomycosis Market by Country, 2018 - 2021, USD Million
  • TABLE 22 North America Onychomycosis Market by Country, 2022 - 2028, USD Million
  • TABLE 23 US Onychomycosis Market, 2018 - 2021, USD Million
  • TABLE 24 US Onychomycosis Market, 2022 - 2028, USD Million
  • TABLE 25 US Onychomycosis Market by Type, 2018 - 2021, USD Million
  • TABLE 26 US Onychomycosis Market by Type, 2022 - 2028, USD Million
  • TABLE 27 US Onychomycosis Market by Treatment, 2018 - 2021, USD Million
  • TABLE 28 US Onychomycosis Market by Treatment, 2022 - 2028, USD Million
  • TABLE 29 Canada Onychomycosis Market, 2018 - 2021, USD Million
  • TABLE 30 Canada Onychomycosis Market, 2022 - 2028, USD Million
  • TABLE 31 Canada Onychomycosis Market by Type, 2018 - 2021, USD Million
  • TABLE 32 Canada Onychomycosis Market by Type, 2022 - 2028, USD Million
  • TABLE 33 Canada Onychomycosis Market by Treatment, 2018 - 2021, USD Million
  • TABLE 34 Canada Onychomycosis Market by Treatment, 2022 - 2028, USD Million
  • TABLE 35 Mexico Onychomycosis Market, 2018 - 2021, USD Million
  • TABLE 36 Mexico Onychomycosis Market, 2022 - 2028, USD Million
  • TABLE 37 Mexico Onychomycosis Market by Type, 2018 - 2021, USD Million
  • TABLE 38 Mexico Onychomycosis Market by Type, 2022 - 2028, USD Million
  • TABLE 39 Mexico Onychomycosis Market by Treatment, 2018 - 2021, USD Million
  • TABLE 40 Mexico Onychomycosis Market by Treatment, 2022 - 2028, USD Million
  • TABLE 41 Rest of North America Onychomycosis Market, 2018 - 2021, USD Million
  • TABLE 42 Rest of North America Onychomycosis Market, 2022 - 2028, USD Million
  • TABLE 43 Rest of North America Onychomycosis Market by Type, 2018 - 2021, USD Million
  • TABLE 44 Rest of North America Onychomycosis Market by Type, 2022 - 2028, USD Million
  • TABLE 45 Rest of North America Onychomycosis Market by Treatment, 2018 - 2021, USD Million
  • TABLE 46 Rest of North America Onychomycosis Market by Treatment, 2022 - 2028, USD Million
  • TABLE 47 Key Information - Abbott Laboratories
  • TABLE 48 key information - Bausch Health Companies, Inc.
  • TABLE 49 Key Information - Bayer AG
  • TABLE 50 Key Information - Cipla Limited
  • TABLE 51 Key Information - Sun Pharmaceutical Industries Ltd.
  • TABLE 52 Key Information - GlaxoSmithKline PLC (GSK)
  • TABLE 53 Key Information - Pfizer, Inc.
  • TABLE 54 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 55 KEY INFORMATION - Merck & Co., Inc.
  • TABLE 56 Key Information - Novartis AG

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Swot analysis: Abbott laboratories
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!